These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Application of recombinant hemagglutinin proteins as alternative antigen standards for pandemic influenza vaccines.
    Author: Choi Y, Kwon SY, Oh HJ, Shim S, Chang S, Chung HJ, Kim DK, Park Y, Lee Y.
    Journal: Biotechnol Lett; 2017 Sep; 39(9):1375-1380. PubMed ID: 28612264.
    Abstract:
    OBJECTIVES: The single radial immunodiffusion (SRID) assay, used to quantify hemagglutinin (HA) in influenza vaccines, requires reference reagents; however, because centralized production of reference reagents may slow the emergency deployment of vaccines, alternatives are needed. RESULTS: We investigated the production of HA proteins using recombinant DNA technology, rather than a traditional egg-based production process. The HA proteins were then used in an SRID assay as a reference antigen. We found that HA can be quantified in both egg-based and cell-based influenza vaccines when recombinant HAs (rHAs) are used as the reference antigen. Furthermore, we confirmed that rHAs obtained from strains with pandemic potential, such as H5N1, H7N3, H7N9, and H9N2 strains, can be utilized in the SRID assay. The rHA production process takes just one month, in contrast to the traditional process that takes three to four months. CONCLUSIONS: The use of rHAs may reduce the time required to produce reference reagents and facilitate timely introduction of vaccines during emergencies.
    [Abstract] [Full Text] [Related] [New Search]